HUTCHISON CHINA MEDITECH LTD

Hutchison China MediTech Limited ("Chi-Med")
(AIM: HCM)

Fruquintinib receives SFDA IND approval
Starts Phase I Clinical Trial for the treatment of cancer

London: Tuesday, 1 February 2011: Hutchison MediPharma Limited ("Hutchison MediPharma"), the drug R&D company majority owned by Chi-Med, today announces that it has started the first-in-human Phase I clinical trial of its anti-cancer drug candidate, Fruquintinib. This follows approval from the State Food and Drug Administration ("SFDA") in China. Similar to Hutchison MediPharma's drug candidate Sulfatinib, the investigational new drug (IND) application for Fruquintinib was reviewed through the SFDA's Green Channel expedited application process. The first patients were dosed on 28 January 2011.

Fruquintinib (HMPL-013) is a novel small molecule that selectively inhibits the tyrosine kinase activity associated with vascular endothelial growth factor receptors (VEGFR). Pre-clinical data shows that this compound is a potent suppressor of angiogenesis, an established approach in anti-cancer treatment. In low doses, Fruquintinib has potent inhibitory effects on multiple human tumour xenografts, including some hard-to-treat tumours such as pancreatic cancer and melanoma. It is differentiated from Sulfatinib and other drugs in this class either on the market or in clinical development by its kinase selectivity *in vitro* and superior potency *in vivo* against a variety of human tumour xenografts. Fruquintinib was discovered and developed internally by Hutchison MediPharma.

The Phase I clinical study is being conducted in China. The trial is an open-label, dose-escalation study. The primary objective of the trial is to determine the maximum tolerated dose (MTD) and assess the safety and tolerability in patients with advanced solid tumours. The secondary objectives include the assessment of single and multiple dose pharmacokinetics and the evaluation of Fruquintinib's antitumor activity.

Dr. Samantha Du, Chief Scientific Officer of Chi-Med and Chief Executive Officer of Hutchison MediPharma, said: "This is further evidence of our capabilities in innovative drug discovery and development and moves another of our pipeline of anti-cancer agents into clinical development. Fruquintinib is highly selective of all three forms of VEGFR, as well as having potent activity against aggressive tumours. Starting the Phase I trials takes an additional step toward our goal of developing more effective and safe anti-cancer agents for patients globally."

Ends

Enquiries

Chi-Med	Telephone:	+852 2121 8200
Christian Hogg, CEO		
Citigate Dewe Rogerson	Telephone:	+44 (0) 20 7638 9571
Anthony Carlisle	Mobile:	+44 (0) 7973 611 888
David Dible	Mobile:	+44 (0) 7967 566 919
Lazard & Co., Limited	Telephone:	+44 (0) 20 7187 2000
Paul Gismondi		
Nick Fowler		

Notes to Editors

About the Vascular Endothelial Growth Factor in Cancer Tumours

Angiogenesis, the process of developing new blood vessels, is critical for tumour cell growth, survival, invasion and metastasis. The vascular endothelial growth factor (VEGF) and VEGF receptors (VEGFRs) play a pivotal role in tumour-related angiogenesis, and the VEGF/VEGFR pathway is an important target for anti-angiogenic drug development and tumour therapy. Inhibition of VEGF signalling in tumour vasculature therefore represents an exciting therapeutic strategy, with the potential to arrest the development of new blood vessels essential for tumour growth and metastasis. Several anti-VEGF agents have shown efficacy in a range of tumour types.

Fruquintinib is a potent, selective, small molecule tyrosine kinase inhibitor of VEGF receptors 1, 2 and 3. In animal studies, Fruquintinib demonstrated broad spectrum anti-tumour efficacy via oral dosing in multiple tumour xenografts.

About Hutchison MediPharma

Hutchison MediPharma is a novel pharmaceutical research & development company focused on discovering, developing and commercializing innovative therapeutics in oncology and autoimmune diseases. With a team of well over 200 scientists, its pipeline includes novel oral compounds for cancer and inflammation in development in North America, Europe, Australia and Greater China.

Hutchison MediPharma is majority owned by Chi-Med.

For more information, please visit: http://www.hmplglobal.com

About Chi-Med

Chi-Med is the holding company of a healthcare group based primarily in China and was listed on the Alternative Investment Market of the London Stock Exchange in May 2006. It is focused on researching, developing, manufacturing and selling pharmaceuticals and health oriented consumer products.

Chi-Med is majority owned by Hutchison Whampoa Limited, an international company listed on the Main Board of The Stock Exchange of Hong Kong Limited.

For more information, please visit: http://www.chi-med.com